Blood-Brain Barrier Summit

The blood-brain barrier (BBB) is an extremely complex interface brimming with tricks and secrets we need to elucidate.

Now in its 3rd year, the Blood-Brain Barrier Summit is the industry's definitive blood-brain barrier conference, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for CNS drug developers.

Whatever approach you are working on, we have collated a comprehensive variety of topics to showcase the latest scientific advances across this very competitive field.

Building on the success of last year's meeting, this year's program will uncover how leading companies and academics are working to enhance BBB penetration through the use of antibody therapies, nanoparticle engineering, AAV capsids, focused ultrasound, extracellular vesicles and more! New for this year we also explore the mechanisms of SARS-CoV-2 brain entry.

As we gather the best minds in this ever-challenging field, from the likes of AbbVie, Novartis, Roche, Merck and Ossianix, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists.

URLs:
Tickets: https://go.evvnt.com/751171-2?pid=176
Brochure: https://go.evvnt.com/751171-3?pid=176

Prices:
Conference + 2 Workshops - Drug Developer: USD 2697.0,
Conference + 1 Workshop - Drug Developer: USD 2298.0,
Conference Only - Drug Developer: USD 1899.0,
Conference + 2 Workshops - Academic and Non-Profit: USD 2297.0,
Conference + 1 Workshop - Academic and Non-Profit: USD 1898.0,
Conference Only - Academic and Non-Profit: USD 1499.0,
Conference + 2 Workshops - Service Provider: USD 3097.0,
Conference + 1 Workshop - Service Provider: USD 2698.0,
Conference Only - Service Provider: USD 2299.0

Speakers: Katherine Deng, Principal Scientist, AbbVie, Sungwon An, Director, ABL Bio, Steve Stice, CSO, Aruna Bio, Anna Jezierski, Research Officer, Human Health Therapeutics Research Centre, National Research Council of Canada, Danica Stanimirovic, Director, Translational Bioscience, Human Health Therapeutics Research Centre, National Research Council of Canada, Will Costain, Senior Research Officer, Human Health Therapeutics Research Centre National Research Council of Canada, Jean-François Ghersi-Egea, Research Director, INSERM, Raleigh Linville, Post-doc, Searson Group, Johns Hopkins Institute for NanoBioTechnology, Susan Rosenbaum, Founder, Chairman, CEO, Lauren Sciences LLC, Karin Otte, Principal Scientist, Merck, Jonathan Sugam, Associate, Principal Scientist, Neuroscience Discovery, Merck, Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society, Moein Moghimi, Professor of Pharmaceutics and Nanomedicine, Newcastle University, Manuel Sanchez-Felix, Senior Fellow, Novel Delivery Technologies, Novartis Institute for Biomedical Research, Pawel Stocki, Director of Research, Ossianix, Felix Schumacher, Program Leader Targeted Therapeutics, Roche, Peter Westenskow, Senior Principal Scientist and Section Head, Roche, Stina Syvanen, Associate Professor, Uppsala University, Nathalie Agar, Associate Professor of Neurosurgery and Radiology, Harvard Medical School, Michelle Erickson, Research Assistant Professor, Department of Medicine/Division of Gerontology and Geriatric Medicine, University of Washington Research Biologist, VA Puget Sound Healthcare System, Carsten Hagemann, Head of the Tumorbiology Laboratory, Department of Neurosurgery, University Hospital Wuerzburg, Nathalie Cartier, Head of NeurogenCell Lab, Paris Brain Institute (ICM), INSERM, Paris Sorbonne University, CNS Expert, Asklepios BioPharmaceutical, Amber D. Van Laar, VP Clinical Development, Asklepios BioPharmaceutical, Inc, William A. Banks, Associate Chief of Staff - Research and Development, VA Puget Sound Professor, Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington

Time: 10:00 - 17:00